|
CANAVESE G.-DOZIN B.-VECCHIO C.-TOMEI D.-VILLA G.-CARLI F.-DEL
MASTRO L.-LEVAGGI A.-ROSSELLO C.-SPINACI S.-BRUZZI P.-CATTURICH A.
Accuracy of sentinel lymph node biopsy after neo adjuvant
chemotherapy in patients with locally advanced breast cancer and
clinically positive axillary nodes.
Eur. J. Surg. Oncol. 37:688/694, 2011
PubMed Abstract
DEL MASTRO L.-GIRAUDI S.-LEVAGGI A.-PRONZATO P.
Medical approaches to preservation of fertility in female cancer
patients.
Expert. Opin. Pharmacother. 12(3):387/396, 2011
PubMed Abstract
LAMBERTINI M.-PRONZATO P.-GIRAUDI S.-LEVAGGI A.-BIGHIN C.-DEL
MASTRO L.
Letrozole withdrawal response in locally advanced breast cancer.
Letter.
Ann. Oncol. 22:1927/1928, 2011
PubMed Abstract
SMITH I.E.-PIERGA J.-BIGANZOLI L.-CORTES FUNES H.-THOMSSEN C.-
PIVOT X.-FABI A.-XU B.-STROYAKOVSKIY D.-FRANKE F.-KAUFMAN B.-
MAINWARING P.-PIENKOWSKI T.-DE VALK B.-KWONG A.-GONZALEZ TRUJILLO
J.-KOZA I.-PETRAKOVA K.-PEREIRA D.-PRITCHARD K.-ATHENA Study Group-
DEL MASTRO L.-SERTOLI M.R.
First line bevacizumab plus taxane based chemotherapy for locally
recurrent or metastatic breast cancer: safety and efficacy in an
open label study in 2251 patients.
Ann. Oncol. 22:595/602, 2011
PubMed Abstract
AZIM Jr H.-DEL MASTRO L.-SCARFONE G.-PECCATORI F.
Treatment of breast cancer during pregnancy: regimen selection,
pregnancy monitoring and more...
Breast 20:1/6, 2011 - Epub Nov 24, 2010
PubMed Abstract
BIGHIN C.-DEL MASTRO L.-CANAVESE G.-CARLI F.-TAVEGGIA P.-LEVAGGI
A.-GIRAUDI S.-PRONZATO P.
Use in current clinical practice of 70 gene signature in early
breast cancer. Letter.
Int. J. Cancer 127:2736/2737, 2010
PubMed Abstract
BIGHIN C.-LUNARDI G.-DEL MASTRO L.-MARRONI P.-TAVEGGIA P.-LEVAGGI
A.-GIRAUDI S.-PRONZATO P.
Estrone sulphate, FSH, and testosterone levels in two male breast
cancer patients treated with aromatase inhibitors.
Oncologist 15:1270/1272, 2010
PubMed Abstract
CORREA C.-MCGALE P.-TAYLOR C.-WANG Y.-CLARKE M.-DAVIES C.-PETO R.-
BIJKER N.-SOLIN L.-DARBY S.-Early Breast Cancer Trialists'
Collaborative Group (EBCTCG)-BOCCARDO F.-RUBAGOTTI A.-BRUZZI P.-
DEL MASTRO L.-PRONZATO P.-SERTOLI M.R.-VENTURINI M.
Overview of the randomized trials of radiotherapy in ductal
carcinoma in situ of the breast.
J. Natl. Cancer Inst. Monogr. 2010(41):162/177, 2010
PubMed Abstract
DEL MASTRO L.-BIGHIN C.-BINI G.-GIRAUDI S.-TAVEGGIA P.-LEVAGGI A.-
CANAVESE G.-RESCINITO G.-PRONZATO P.
Trastuzumab before breast surgery: is concurrent administration
with anthracycline containing chemotherapy necessary? Letter.
Ann. Oncol. 21(6):1376/1377, 2010
PubMed Abstract
DEL MASTRO L.-LEVAGGI A.-GIRAUDI S.-PRONZATO P.
Luteinising hormone releasing hormone agonists (LH/RHa) in
premenopausal early breast cancer patients: current role and
future perspectives.
Cancer Treat. Rev. 37:208/211, 2011 - Epub Aug 17, 2010
PubMed Abstract
GASCON P.-PIRKER R.-DEL MASTRO L.-DURRWELL L.
Effects of CERA (continuous erythropoietin receptor activator) in
patients with advanced non small cell lung cancer (NSCLC)
receiving chemotherapy: results of a phase II study.
Ann. Oncol. 21:2029/2039, 2010
PubMed Abstract
VENTURINI M.-BIGHIN C.-PUGLISI F.-OLMEO N.-AITINI E.-COLUCCI G.-
GARRONE O.-PACCAGNELLA A.-MARINI G.-CRINO' L.-MANSUTTI M.-BACONNET
B.-BARBATO A.-DEL MASTRO L.
A multicentre phase II study of non pegylated liposomal
doxorubicin in combination with trastuzumab and docetaxel as first
line therapy in metastatic breast cancer.
Breast 19:333/338, 2010
PubMed Abstract
BANELLI B.-CASCIANO I.-DI VINCI A.-GATTESCHI B.-LEVAGGI A.-CARLI
F.-BIGHIN C.-SALVI S.-ALLEMANNI G.-GHIORZO P.-PRONZATO P.-
VENTURINI M.-ROMANI M.-DEL MASTRO L.
Pathological and molecular characteristics distinguishing
contralateral metastatic from new primary breast cancer.
Ann. Oncol. 21:1237/1242, 2010 - Epub Oct 29, 2009
PubMed Abstract
BIG 1/98 Collaborative Group-MOURIDSEN H.-GIOBBIE HURDER A.-
GOLDHIRSCH A.-THURLIMANN B.-PARIDAENS R.-SMITH I.-MAURIAC L.-
FORBES J.-PRICE K.-REGAN M.-GELBER R.-COATES A.-ROSSO R.-DEL
MASTRO L.-BIGHIN C.
Letrozole therapy alone or in sequence with tamoxifen in women
with breast cancer.
N. Engl. J. Med. 361:766/776, 2009
PubMed Abstract
GIOBBIE HURDER A.-PRICE K.-GELBER R.-International Breast Cancer
Study Group BIG 1/98 Collaborative Group-ROSSO R.-DEL MASTRO L.-
BIGHIN C.
Design, conduct, and analyses of Breast International Group (BIG)
1/98: a randomized, double blind, phase III study comparing
letrozole and tamoxifen as adjuvant endocrine therapy for
postmenopausal women with receptor positive, early breast cancer.
Clin. Trials 6:272/287, 2009
PubMed Abstract
MORABITO A.-DOZIN B.-SALVI S.-PASCIUCCO G.-BALBI G.-LAURENT S.-
PASTORINO S.-CARLI F.-TRUINI M.-BRUZZI P.-DEL MASTRO L.-PISTILLO
M.P.
Analysis and clinical relevance of human leukocyte antigen class
I, heavy chain, and beta2/microglobulin downregulation in breast
cancer.
Hum. Immunol. 70:492/495, 2009
PubMed Abstract
RABAGLIO M.-SUN Z.-PRICE K.-CASTIGLIONE GERTSCH M.-HAWLE H.-
THURLIMANN B.-MOURIDSEN H.-CAMPONE M.-FORBES J.-PARIDAENS R.-
COLLEONI M.-PIENKOWSKI T.-NOGARET J.-LANG I.-SMITH I.-GELBER R.-
GOLDHIRSCH A.-COATES A.-BIG 1/98 Collaborative International
Breast Cancer Study Groups-ROSSO R.-DEL MASTRO L.-BIGHIN C.
Bone fractures among postmenopausal patients with endocrine
responsive early breast cancer treated with 5 years of letrozole
or tamoxifen in the BIG 1/98 trial.
Ann. Oncol. 20:1489/1498, 2009
PubMed Abstract
CRIVELLARI D.-SUN Z.-COATES A.-PRICE K.-THURLIMANN B.-MOURIDSEN H.-MAURIAC L.-FORBES J.-PARIDAENS R.-CASTIGLIONE M.-GELBER R.-COLLEONI M.-LANG I.-DEL MASTRO L.-GLADIEFF L.-RABAGLIO M.-SMITH I.-CHIRGWIN J.-GOLDHIRSCH A.
Letrozole compared with tamoxifen for elderly patients with
endocrine responsive early breast cancer: the BIG 1/98 trial.
J. Clin. Oncol. 26:1972/1979, 2008
PubMed Abstract
DEL MASTRO L.
The difficult decision making process for using or not using
adjuvant chemotherapy in premenopausal endocrine responsive breast
cancer patients.
Ann. Oncol. 19:1213/1215, 2008
PubMed Abstract
PICCIOLI P.-SERRA M.-PEDEMONTE S.-BALBI G.-LOIACONO F.-LASTRAIOLI
S.-GARGIULO L.-MORABITO A.-ZUCCARO D.-DEL MASTRO L.-PISTILLO M.P.-VENTURINI M.-DE ANGIOLETTI M.-NOTARO R.
Hexaprimer amplification refractory mutation system PCR for
simultaneous single tube genotyping of 2 close polymorphisms.
Letter.
Clin. Chem. 54:227/229, 2008
PubMed Abstract
VIALE G.-GIOBBIE HURDER A.-REGAN M.-COATES A.-MASTROPASQUA M.-
DELL'ORTO P.-MAIORANO E.-MACGROGAN G.-BRAYE S.-OHLSCHLEGEL C.-
NEVEN P.-OROSZ Z.-OLSZEWSKI W.-KNOX F.-THURLIMANN B.-PRICE K.-
CASTIGLIONE GERTSCH M.-GELBER R.-GUSTERSON B.-GOLDHIRSCH A.-Breast
International Group Trial 1/98-ROSSO R.-DEL MASTRO L.-BIGHIN C.
Prognostic and predictive value of centrally reviewed Ki/67
labeling index in postmenopausal women with endocrine responsive
breast cancer: results from Breast International Group Trial 1/98
comparing adjuvant tamoxifen with letrozole.
J. Clin. Oncol. 26:5569/5575, 2008
PubMed Abstract
CLAVAREZZA M.-DEL MASTRO L.-PRONZATO P.-BRUZZI P.-VENTURINI M.
Re: acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony stimulating factors during breast cancer
adjuvant chemotherapy. Letter.
J. Natl. Cancer Inst. 99:1050/1051, 2007
COATES A.-KESHAVIAH A.-THURLIMANN B.-MOURIDSEN H.-MAURIAC L.-FORBES J.-PARIDAENS R.-CASTIGLIONE M.-GELBER R.-COLLEONI M.-LANG
I.-DEL MASTRO L.-SMITH I.-CHIRGWIN J.-NOGARET J.-PIENKOWSKI T.-WARDLEY A.-JAKOBSEN E.-PRICE K.-GOLDHIRSCH A.
Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine
responsive early breast cancer: update of study BIG 1/98.
J. Clin. Oncol. 25:486/492, 2007
PubMed Abstract
COOMBES R.-KILBURN L.-SNOWDON C.-PARIDAENS R.-COLEMAN R.-JONES S.-JASSEM J.-VAN DE VELDE C.-DELOZIER T.-ALVAREZ I.-DEL MASTRO L.-
ORTMANN O.-DIEDRICH K.-COATES A.-BAJETTA E.-HOLMBERG S.-DODWELL D.-MICKIEWICZ E.-ANDERSEN J.-LONNING P.-COCCONI G.-FORBES J.-
CASTIGLIONE M.-STUART N.-STEWART A.-FALLOWFIELD L.-BERTELLI G.-HALL E.-BOGLE R.-CARPENTIERI M.-COLAJORI E.-SUBAR M.-IRELAND E.-BLISS J.
Survival and safety of exemestane versus tamoxifen after 2/3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial.
Lancet 369:559/570, 2007
PubMed Abstract
DEL MASTRO L.-CLAVAREZZA M.-VENTURINI M.
Reducing the risk of distant metastases in breast cancer patients: role of
aromatase inhibitors.
Cancer Treat. Rev. 33:681/687, 2007
PubMed Abstract
DEL MASTRO L.-DOZIN B.-AITINI E.-CATZEDDU T.-BALDINI E.-CONTU A.-DURANDO A.-DANESE
S.-CAVAZZINI G.-CANAVESE G.-BRUZZI P.-PRONZATO P.-VENTURINI M.
Timing of adjuvant chemotherapy and tamoxifen in women with breast cancer:
findings from two consecutive trials of Gruppo Oncologico Nord Ovest Mammella
Intergruppo (GONO/MIG) Group.
Ann. Oncol. 19:299/307, 2008 - Epub Oct 17, 2007
PubMed Abstract
GRIDELLI C.-FERRARA C.-GUERRIERO C.-PALAZZO S.-GRASSO G.-PAVESE I.-SATTA F.-BAJETTA E.-CORTINOVIS D.-BARBIERI F.-GEBBIA V.-GROSSI F.-
NOVELLO S.-BALDINI E.-GASPARINI G.-LATINO W.-DURANTE E.-GIUSTINI L.-NEGRINI C.
Informal caregiving burden in advanced non small cell lung cancer: the HABIT study.
J. Thorac. Oncol. 2:475/480, 2007
PubMed Abstract
CLAVAREZZA M.-DEL MASTRO L.-VENTURINI M.
Taxane containing chemotherapy in the treatment of early breast cancer patients.
Ann. Oncol. 17(suppl):vii22/vii26, 2006
PubMed Abstract
DEL MASTRO L.-CATZEDDU T.-BONI L.-BELL C.-SERTOLI M.R.-BIGHIN C.-CLAVAREZZA M.-TESTA D.-VENTURINI M.
Prevention of chemotherapy induced menopause by temporary ovarian suppression with goserelin in young, early breast cancer patients.
Ann. Oncol. 17:74/78, 2006
PubMed Abstract
DEL MASTRO L.-CATZEDDU T.-VENTURINI M.
Infertility and pregnancy after breast cancer: current knowledge and future perspectives.
Cancer Treat. Rev. 32:417/422, 2006
PubMed Abstract
DEL MASTRO L.-VENTURINI M.
Fertility preservation strategies for breast cancer patients. Letter.
J. Clin. Oncol. 24:4220/4221, 2006
PubMed Abstract
VENTURINI M.-BIGHIN C.-MONFARDINI S.-CAPPUZZO F.-OLMEO N.-DURANDO A.-PUGLISI F.-NICOLETTO O.-LAMBIASE A.-DEL MASTRO L.
Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first line treatment for HER2
overexpressing metastatic breast cancer.
Breast Cancer Res. Treat. 95:45/53, 2006
PubMed Abstract
VENTURINI M.-DEL MASTRO L.
Safety of adjuvant aromatase inhibitor therapy.
Cancer Treat. Rev. 32:548/556, 2006
PubMed Abstract
Per le pubblicazioni 2000-2005 del personale della struttura vedere gli
elenchi generali.
|
Presentazione della struttura